SCHEDULE: FMR LLC Discloses 6.1% Stake in Bicara Therapeutics
Ownership Disclosure
FMR LLC and Abigail P. Johnson have reported a 6.1% beneficial ownership stake in Bicara Therapeutics Inc. common stock.
Summary
- FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, beneficially own 3,347,223 shares of Bicara Therapeutics Inc. common stock.
- This represents 6.1% of the total outstanding common stock of Bicara Therapeutics Inc.
- FMR LLC holds sole voting power over 3,346,671 shares and sole dispositive power over 3,347,223 shares.
- Abigail P. Johnson, as a controlling person of FMR LLC, is also deemed to beneficially own 3,347,223 shares with sole dispositive power.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
- The securities were not acquired for the purpose of changing or influencing the control of Bicara Therapeutics Inc.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a major institutional investor like FMR LLC typically indicates a belief in the company's value or future potential, though the filing itself is purely a disclosure of ownership.
Positives
- A significant institutional investor like FMR LLC holding a 6.1% stake can be viewed as a vote of confidence in Bicara Therapeutics Inc.
- The beneficial ownership by FMR LLC, a major financial services firm, may attract further institutional interest in Bicara Therapeutics Inc.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Bicara Therapeutics Inc.'s future performance or operations.
Industry Context
StockSavvy.ai notes that the disclosure of a significant stake by a prominent asset manager like FMR LLC in a biotechnology company such as Bicara Therapeutics Inc. often signals institutional confidence in the company's long-term prospects or its therapeutic pipeline. This type of institutional investment can be a positive indicator for other investors, potentially influencing market perception and liquidity, especially in the often volatile biotech sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may enhance investor confidence and potentially influence stock valuation.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC's signatory. |
| 2023-01-10 | Date of previous Schedule 13G filing by FMR LLC, referenced for Power of Attorney. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson's signatory. |
| 2023-01-31 | Date of previous Schedule 13G filing by FMR LLC, referenced for Abigail P. Johnson's Power of Attorney. |
| 2025-12-31 | Date of event which requires filing of this statement. |
| 2026-02-04 | Signature date for FMR LLC and Abigail P. Johnson on the Schedule 13G. |
Keywords
Bicara Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Institutional Ownership, Common Stock, SEC Filing, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.